Signatera Assessment in Early-Stage Endometrial Cancer
NCT: NCT07339384 · NOT_YET_RECRUITING
Brief Summary
The goal of this clinical trial is to assess if circulating tumor DNA can guide adjuvant selection in high-intermediate risk early-stage endometrial cancer. The main question it aims to answer is: • To evaluate if 3-year recurrence-free survival among women with Stage I, high-intermediate risk endometrial cancer who are ctDNA negative after receiving ctDNA-guided observation is non-inferior to adjuvant vaginal brachytherapy (an internal radiation therapy) Researchers will compare high-risk intermediate ctDNA negative participants who are observed to those who receive vaginal brachytherapy to see if they have similar outcomes. Participants will be asked to: * Receive serial ctDNA testing * Visit their study doctor per their standard of care visits about every 3 months for 2 years * Answer a questionnaire about their well-being
Frequently Asked Questions
What is Signatera Assessment in Early-Stage Endometrial Cancer?
Signatera Assessment in Early-Stage Endometrial Cancer is a clinical trial registered under NCT07339384. Current status: NOT_YET_RECRUITING.
What is the status of NCT07339384?
The current status of NCT07339384 (Signatera Assessment in Early-Stage Endometrial Cancer) is: NOT_YET_RECRUITING.
When did Signatera Assessment in Early-Stage Endometrial Cancer start?
Signatera Assessment in Early-Stage Endometrial Cancer started on 2026-05.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.